Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

  • Interventional
  • Recruiting
  • NCT03592641

A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer

This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.